RB1 and non-small cell lung carcinoma: A recent clinical study with a cohort of advanced NSCLC patients (with stage III and IV disease) showed that RB mutant status was strongly associated with worse outcomes in patients, with median overall survival of 8.3 months for patients with mutant RB compared to 28.3 months for patients with wild-type RB [35].